PD-1/PD-L1 Blockade Accelerates the Progression of Atherosclerosis in Cancer Patients

Area of Science:

• Cardiovascular Medicine
• Oncology
• Immunology

Background:

• Programmed death-1 (PD-1)/PD-L1 blockade is a significant advancement in cancer therapy.
• This immunotherapy can lead to adverse cardiovascular events, including acute coronary syndrome (ACS).
• The PD-1/PD-L1 axis has been previously linked to atherosclerosis development.

Purpose of the Study:

• To explore the hypothesis that PD-1/PD-L1 blockade accelerates atherosclerosis and promotes plaque rupture.
• To synthesize evidence regarding vascular inflammation and plaque dynamics under PD-1/PD-L1 blockade.
• To highlight the importance of early ACS recognition in patients receiving PD-1/PD-L1 blockade.

Main Methods:

• Literature review synthesizing evidence on PD-1/PD-L1 blockade and cardiovascular effects.
• Analysis of studies linking PD-1/PD-L1 axis to vascular inflammation and atherosclerosis progression.
• Examination of T-cell activation and effector functions in the context of plaque destabilization.

Main Results:

• Evidence suggests PD-1/PD-L1 blockade may accelerate atherosclerosis progression.
• The blockade might promote plaque destabilization and rupture through T-cell mediated mechanisms.
• PD-1/PD-L1 blockade-related ACS, though rare, carries a significant risk of fatality.

Conclusions:

• PD-1/PD-L1 blockade may exacerbate atherosclerosis and increase the risk of plaque rupture.
• Early identification of ACS in patients undergoing PD-1/PD-L1 blockade is crucial for improving prognosis.
• Managing cardiotoxicity is essential for optimizing cancer patient outcomes with immunotherapy.